Literature DB >> 10683002

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

J P Julien1, N Bijker, I S Fentiman, J L Peterse, V Delledonne, P Rouanet, A Avril, R Sylvester, F Mignolet, H Bartelink, J A Van Dongen.   

Abstract

BACKGROUND: Ductal carcinoma in situ (DCIS) of the breast is a disorder that has become more common since it may manifest as microcalcifications that can be detected by screening mammography. Since selected women with invasive cancer can be treated safely with breast conservation therapy it is paradoxical that total mastectomy has remained the standard treatment for DCIS. We did a randomised phase III clinical trial to investigate the role of radiotherapy after complete local excision of DCIS.
METHODS: Between 1986 and 1996, women with clinically or mammographically detected DCIS measuring less than or equal to 5 cm were treated by complete local excision of the lesion and then randomly assigned to either no further treatment (n=503) or to radiotherapy (n=507; 50 Gy in 5 weeks to the whole breast). The median duration of follow-up was 4.25 years (maximum 12.0 years). All analyses were by intention to treat.
FINDINGS: 500 patients were followed up in the no further treatment group and 502 in the radiotherapy group. In the no further treatment group 83 women had local recurrence (44 recurrences of DCIS, and 40 invasive breast cancer). In the radiotherapy group 53 women had local recurrences (29 recurrences of DCIS, and 24 invasive breast cancer). The 4-year local relapse-free was 84% in the group treated with local excision alone compared with 91% in the women treated by local excision plus radiotherapy (log rank p=0.005; hazard ratio 0.62). Similar reductions in the risk of invasive (40%, p=0.04) and non-invasive (35%, p=0.06) local recurrence were seen.
CONCLUSIONS: Radiotherapy after local excision for DCIS, as compared with local excision alone, reduced the overall number of both invasive and non-invasive recurrences in the ipsilateral breast at a median follow-up of 4.25 years.

Entities:  

Mesh:

Year:  2000        PMID: 10683002     DOI: 10.1016/s0140-6736(99)06341-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  91 in total

Review 1.  Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update).

Authors:  I Olivotto; M Levine
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 2.  A role for antiangiogenic therapy in breast cancer.

Authors:  Marsha A Moses; Jay Harper; Cecilia A Fernández
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

3.  An adequate margin of excision in ductal carcinoma in situ.

Authors:  Malcolm R Kell; Monica Morrow
Journal:  BMJ       Date:  2005-10-08

4.  Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey.

Authors:  R Brian Haynes; K Ann McKibbon; Nancy L Wilczynski; Stephen D Walter; Stephen R Werre
Journal:  BMJ       Date:  2005-05-13

5.  Breast cancer guidelines for Uganda (2nd Edition 2008).

Authors:  A Gakwaya; M Galukande; A Luwaga; J Jombwe; J Fualal; E Kiguli-Malwadde; P Baguma; A Kanyike; J B Kigula-Mugamba
Journal:  Afr Health Sci       Date:  2008-06       Impact factor: 0.927

6.  Racial disparities in travel time to radiotherapy facilities in the Atlanta metropolitan area.

Authors:  Lucy A Peipins; Shannon Graham; Randall Young; Brian Lewis; Barry Flanagan
Journal:  Soc Sci Med       Date:  2013-04-29       Impact factor: 4.634

7.  Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.

Authors:  I Kong; S A Narod; C Taylor; L Paszat; R Saskin; S Nofech-Moses; D Thiruchelvam; W Hanna; J P Pignol; S Sengupta; L Elavathil; P A Jani; S J Done; S Metcalfe; E Rakovitch
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

8.  Clinical experience of patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery plus radiotherapy: a preliminary report.

Authors:  Ji-Young Jang; Mi-Ryeong Ryu; Sung-Whan Kim; Chul-Seung Kay; Yeon-Sil Kim; Yoon-Kyeong Oh; Hyung-Chul Kwon; Sei-Chul Yoon; Woo-Chan Park; Byung-Joo Song; Se-Jeong Oh; Sang-Seol Jung; Jong-Man Won; Seung-Nam Kim; Su-Mi Chung
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

9.  Reconstruction in Breast Conservation Therapy-Single Tertiary Care Institution Experience with 472 Patients.

Authors:  Juhi Agrawal; Sandeep Mehta; Ashish Goel; Veda Padmapriya Selvakumar; Kapil Kumar; Pankaj Kumar Pande
Journal:  Indian J Surg Oncol       Date:  2017-05-05

10.  Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Patricia A Cronin; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2016-05-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.